Targeted Drug Delivery Using Nanozymes for Improved Rheumatoid Arthritis Outcomes
DOI:
https://doi.org/10.47611/jsrhs.v13i4.7797Keywords:
Rheumatoid Arthritis, Nanoparticle, Nanozyme, Reactive Oxygen Species, CytokinesAbstract
Nanozymes, enzyme-like nanomaterials, offer a novel therapeutic approach for rheumatoid arthritis (RA), characterized by severe joint inflammation and cartilage destruction. Traditional RA treatments, such as NSAIDs, immunosuppressants, and biologics, often cause significant side effects and do not directly address the underlying causes of the disease. Nanozymes offer unique properties, including high stability, tunable catalytic activity, and biocompatibility, making them promising candidates for RA therapy. Recent advancements show the efficacy of nanozyme-functionalized exosomes, hydrogels, and encapsulated drugs in targeting inflamed joints, reducing oxidative stress, and promoting cartilage regeneration. Specifically, ultra-small Prussian blue nanoparticle exosomes (uPB-Exo) have shown superior anti-inflammatory effects and targeted delivery capabilities, significantly improving joint health in RA models. These innovative nanozyme-based treatments represent a significant step forward in RA management, promising enhanced therapeutic efficacy with reduced side effects. Further research and clinical trials are essential to validate these findings and optimize nanozyme applications in autoimmune disease therapy.
Downloads
References or Bibliography
Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. Bioengineering & Translational
Medicine, 4(3), e10143. https://doi.org/10.1002/btm2.10143
Cooper, G. S., & Stroehla, B. C. (2003). The epidemiology of autoimmune diseases. Autoimmunity Reviews, 2(3),
–125. https://doi.org/10.1016/S1568-9972(03)00006-5
Delves Peter J. & Roitt Ivan M. (2000). The Immune System. New England Journal of Medicine, 343(1), 37–49.
https://doi.org/10.1056/NEJM200007063430107
Elkhalifa, S., et al. (2018). Autoimmune Disease: Treatment (pp. 1–11).
https://doi.org/10.1002/9780470015902.a0001437.pub3
Firestein, G. S. (2003). Evolving concepts of rheumatoid arthritis. Nature, 423(6937), 356–361.
https://doi.org/10.1038/nature01661
Huang, Y., et al. (2019). Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and
Applications. Chemical Reviews, 119(6), 4357–4412. https://doi.org/10.1021/acs.chemrev.8b00672
Jia, M., Ren, et al. (2023). Messenger Nanozyme for Reprogramming the Microenvironment of Rheumatoid
Arthritis. ACS Applied Materials & Interfaces, 15(1), 338–353. https://doi.org/10.1021/acsami.2c16458
Jiang, Z., et al. (2023). Fe-curcumin nanozyme-mediated immunosuppression and anti-inflammation in experimental
autoimmune uveitis. Biomaterials Research, 27(1), 131. https://doi.org/10.1186/s40824-023-00451-1
Li, D.-P., et al. (2023). A global assessment of incidence trends of autoimmune diseases from 1990 to 2019 and
predicted changes to 2040. Autoimmunity Reviews, 22(10), 103407. https://doi.org/10.1016/j.autrev.2023.103407
Liang, M., & Yan, X. (2019). Nanozymes: From New Concepts, Mechanisms, and Standards to Applications.
Accounts of Chemical Research, 52(8), 2190–2200. https://doi.org/10.1021/acs.accounts.9b00140
Mekuye, B., & Abera, B. (2023). Nanomaterials: An overview of synthesis, classification, characterization, and
applications. Nano Select, 4(8), 486–501. https://doi.org/10.1002/nano.202300038
Sahu, T., et al.(2021). Nanotechnology based drug delivery system: Current strategies and emerging therapeutic
potential for medical science. Journal of Drug Delivery Science and Technology, 63, 102487.
https://doi.org/10.1016/j.jddst.2021.102487
Shah, B. (2023, February). Rheumatoid Arthritis. https://rheumatology.org/patients/rheumatoid-arthritis
Smith, J. B., & Haynes, M. K. (2002). Rheumatoid Arthritis—A Molecular Understanding. Annals of Internal
Medicine, 136(12), 908–922. https://doi.org/10.7326/0003-4819-136-12-200206180-00012
Sudres, M., et al. (2018). Pathophysiological mechanisms of autoimmunity. Annals of the New York Academy of
Sciences, 1413(1), 59–68. https://doi.org/10.1111/nyas.13560
Wang, L., et al. (2015). Human autoimmune diseases: A comprehensive update. Journal of Internal Medicine,
(4), 369–395. https://doi.org/10.1111/joim.12395
Weyand, C. M., & Goronzy, J. J. (2021). The immunology of rheumatoid arthritis. Nature Immunology, 22(1),
–18. https://doi.org/10.1038/s41590-020-00816-x
Yang, W., et al. (2021). Nanozymes: Activity origin, catalytic mechanism, and biological application. Coordination
Chemistry Reviews, 448, 214170. https://doi.org/10.1016/j.ccr.2021.214170
Zhang, L., et al.(2022). Nanoenzyme engineered neutrophil-derived exosomes attenuate joint injury in advanced
rheumatoid arthritis via regulating inflammatory environment. Bioactive Materials, 18, 1–14.
https://doi.org/10.1016/j.bioactmat.2022.02.017
Zhao, Y., et al. (2022). Nanozyme-reinforced hydrogel as a H2O2-driven oxygenerator for enhancing prosthetic
interface osseointegration in rheumatoid arthritis therapy. Nature Communications, 13(1), 6758.
https://doi.org/10.1038/s41467-022-34481-5
Zhou, F., et al. (2023). Redox Homeostasis Strategy for Inflammatory Macrophage Reprogramming in Rheumatoid
Arthritis Based on Ceria Oxide Nanozyme-Complexed Biopolymeric Micelles. ACS Nano, 17(5), 4358–4372.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Anaahita Kaashyap; Zachary Reinstein
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
